User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Search

Displaying 8 results.
    • Journal article
    Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    Cortés, Javier Kim, Sung-Bae Chung, Wei-Pang Im, Seock-Ah Park, Yeon Hee Hegg, Roberto Kim, Min Hwan Tseng, Ling-Ming Petry, Vanessa Chung, Chi-Feng Iwata, Hiroji Hamilton, Erika Curigliano, Giuseppe Xu, Binghe Huang, Chiun-Sheng Kim, Jee Hyun Chiu, Joanne W Y Pedrini, Jose Luiz Lee, Caleb Liu, Yali Cathcart, Jillian Bako, Emarjola Verma, Sunil Hurvitz, Sara A DESTINY-Breast03 Trial Investigators Taylor, Donatienne[UCL] (2022) The New England journal of medicine — Vol. 386, no.12, p. 1143-1154 (2022)
    • Journal article
    Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.
    Ajani, Jaffer El Hajbi, Farid Cunningham, David Alsina, Maria Thuss-Patience, Peter Scagliotti, Giorgio V Van den Eynde, Marc[UCL] Kim, Sung-Bae Kato, Ken Shen, Lin Li, Liyun Ding, Ningning Shi, Jingwen Barnes, Gisoo Van Cutsem, Eric (2024) ESMO open — Vol. 9, no.1, p. 102202 [1-9] (2024)
    • Journal article
    Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
    Pant, Shubham Schuler, Martin Iyer, Gopa Witt, Olaf Doi, Toshihiko Qin, Shukui Tabernero, Josep Reardon, David A Massard, Christophe Minchom, Anna Lugowska, Iwona Carranza, Omar Arnold, Dirk Gutierrez, Martin Winter, Helen Stuyckens, Kim Crow, Lauren Najmi, Saltanat Hammond, Constance Thomas, Shibu Santiago-Walker, Ademi Triantos, Spyros Sweiti, Hussein Loriot, Yohann Carranza, Omar Greco, Martin Alberto Coward, Jim Joshua, Anthony Karapetis, Christos Hart, Christopher Zhang, Alison Prenen, Hans Goeminne, Jean-Charles Machiels, Jean-Pascal[UCL] Rottey, Sylvie Corassa, Marcelo Molin, Graziela Zibetti Dal Tiscoski, Katsuki Jardim, Denis Leonardo Fontes Mak, Milena Fu, Wei Yao, Herui Huang, Jing Jiang, Haiping Qin, Shukui Chen, Baoshi Yan, Dong Yang, Yu Loriot, Yohann Le Tourneau, Christophe Penel, Nicolas Salas, Sébastien Blay, Jean-Yves Brachet, Pierre-Emmanuel Durando, Xavier Emambux, Sheik Ravaud, Alain Folprecht, Gunnar Arnold, Dirk Schuler, Martin Ahrens, Marit Golf, Alexander Haag, Georg Martin Lordick, Florian Desuki, Alexander Cazzaniga, Marina Ciardiello, Fortunato Milella, Michele Koyama, Takafumi Hirooka, Yoshiki Okamoto, Wataru Aogi, Kenjiro Kuboki, Yasutoshi Lee, Jungyun Kim, Sung-Bae Ahn, Myung-Ju Chang, Jong Hee Kim, Yong-Man Nam, Do-Hyun Park, Jae-Sung Lugowska, Iwona Paz-Ares, Luis Moreno, Victor Cervantes, Andres Calvo, Mariona Falcon, Alejandro Gonzalez, Antonio Tabernero, Josep Martinez Bueno, Alejandro García-Corbacho, Javier Longo, Federico Yen, Chia-Jui Chen, Jen-Shi Hou, Ming-Feng Chao, Yee Rau, Kun-Ming Chiu, Tai-Jan Feng, Yin-Hsun Hsu, Chih-Hung Huang, Wen-Tsung Lai, Kuan-Ming Yeh, Su-peng Palmer, Daniel Minchom, Anna Winter, Helen Welsh, Liam Plummer, Ruth Iyer, Gopakumar Gutierrez, Martin Bilen, Mehmet Arrowsmith, Edward Pant, Shubham Spigel, David Robert Zandberg, Dan Paul Doroshow, Deborah Lu-Emerson, Christine Moezi, Mehdi Paulson, Scott Reardon, David Ward, Patrick Chaves, Jorge Grigg, Claud Hussein, Atif Manda, Sudhir Monticelli, Michael Qamar, Rubina Richey, Stephen L Tamura, David Wilks, Sharon (2023) The Lancet Oncology — Vol. 24, no.8, p. 925-935 (2023)
    • Journal article
    A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
    Kuemmel, Sherko Campone, Mario Loirat, Delphine Lopez, Rafael Lopez Beck, J Thaddeus De Laurentiis, Michelino Im, Seock-Ah Kim, Sung-Bae Kwong, Ava Steger, Guenther G Adelantado, Esther Zamora Duhoux, François[UCL] Greil, Richard Kuter, Irene Lu, Yen-Shen Tibau, Ariadna Özgüroğlu, Mustafa Scholz, Christian W Singer, Christian F Vega, Estela Wimberger, Pauline Zamagni, Claudio Couillebault, Xuan-Mai Fan, Liqiong Guerreiro, Nelson Mataraza, Jennifer Sand-Dejmek, Janna Chan, Arlene (2022) Clinical cancer research — Vol. 28, no. 1, p. 106-115 (2022)
    • Journal article
    6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).
    Cardoso, Fatima Paluch-Shimon, Shani Schumacher-Wulf, Eva Matos, Leonor Gelmon, Karen Aapro, Matti S Bajpai, Jyoti Barrios, Carlos H Bergh, Jonas Bergsten-Nordström, Elizabeth Biganzoli, Laura Cardoso, Maria João Carey, Lisa A Mac Gregor, Mariana Chavez Chidebe, Runcie Cortés, Javier Curigliano, Giuseppe Dent, Rebecca A El Saghir, Nagi S Eniu, Alexandru Fallowfield, Lesley Francis, Prudence A Franco Millan, Sandra X Gilchrist, Jenny Gligorov, Joseph Gradishar, William J Haidinger, Renate Harbeck, Nadia Hu, Xichun Kaur, Ranjit Kiely, Belinda Kim, Sung-Bae Koppikar, Smruti Kuper-Hommel, Marion J J Lecouvet, Frédéric E Mason, Ginny Mertz, Shirley A Mueller, Volkmar Myerson, Claire Neciosup, Silvia Offersen, Birgitte V Ohno, Shinji Pagani, Olivia Partridge, Ann H Penault-Llorca, Frédérique Prat, Aleix Rugo, Hope S Senkus, Elzbieta Sledge, George W Swain, Sandra M Thomssen, Christoph Vorobiof, Daniel A Vuylsteke, Peter[UCL] Wiseman, Theresa Xu, Binghe Costa, Alberto Norton, Larry Winer, Eric P (2024) Breast (Edinburgh, Scotland) — Vol. 76, p. 103756 (2024)
    • Report
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Fehm, Tanja Cottone, Francesco Dunton, Kyle André, Fabrice Krop, Ian Park, Yeon Hee De Laurentiis, Michelino Miyoshi, Yasuo Armstrong, Anne Borrego, Manuel Ruiz Yerushalmi, Rinat Duhoux, François[UCL] Takano, Toshimi Lu, Wenjing Egorov, Anton Kim, Sung-Bae (2024)
    • Journal article
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Fehm, Tanja Cottone, Francesco Dunton, Kyle André, Fabrice Krop, Ian Park, Yeon Hee De Laurentiis, Michelino Miyoshi, Yasuo Armstrong, Anne Borrego, Manuel Ruiz Yerushalmi, Rinat Duhoux, François[UCL] Takano, Toshimi Lu, Wenjing Egorov, Anton Kim, Sung-Bae (2024) The Lancet. Oncology — Vol. 25, no.5, p. 614-625 (2024)
    • Journal article
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    André, Fabrice Hee Park, Yeon Kim, Sung-Bae Takano, Toshimi Im, Seock-Ah Borges, Giuliano Lima, Joao Paulo Aksoy, Sercan Gavila Gregori, Joaquin De Laurentiis, Michelino Bianchini, Giampaolo Roylance, Rebecca Miyoshi, Yasuo Armstrong, Anne Sinha, Rajni Ruiz Borrego, Manuel Lim, Elgene Ettl, Johannes Yerushalmi, Rinat Zagouri, Flora Duhoux, François[UCL] Fehm, Tanja Gambhire, Dhiraj Cathcart, Jillian Wu, Cai Chu, Changan Egorov, Anton Krop, Ian (2023) Lancet — Vol. 401, no. 10390, p. 1773-1785 (2023)